DNJ-20 is an alpha-glucosidase inhibitor with an IC50 of 55.3 µg/mL. It exhibits broad-spectrum activity against SARS-CoV-2. By interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), DNJ-20 hinders the proper processing of viral glycoproteins, thus blocking the formation and infection of viral particles. It is effective against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43, with IC50 values reaching up to 1.49 µM. DNJ-20 can be utilized for pan-coronavirus research.
Molecular Weight:
587.658
CAS Number:
[3081926-49-7]
Formula:
C31H41NO10
Target:
SARS-CoV|||glycosidase
T207025
* VAT and and shipping costs not included. Errors and price changes excepted
